基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 原料药 抗肿瘤药 阿维鲁单抗 Avelumab (Anti-Human PD-L1, Human Antibody)
  • 1537032-82-8Avelumab

1537032-82-8Avelumab

Avelumab (Anti-Human PD-L1, Human Antibody)
询价 1盒 起订
上海 更新日期:2024-11-22

上海一研生物科技有限公司

VIP3年
联系人:吴菲
电话:021-69985186拨打
手机:13611928337 拨打
邮箱:3427709316@qq.com

产品详情:

中文名称:
Avelumab (Anti-Human PD-L1, Human Antibody)
英文名称:
Avelumab (Anti-Human PD-L1, Human Antibody)
CAS号:
1537032-82-8
品牌:
一研
保存条件:
Store at -20°C
产品类别:
抑制剂
Cas:
1537032-82-8

产品属性:

产品名称

规格

CAS

型号

Avelumab (Anti-Human PD-L1, Human Antibody)

1mg 5mg 20mg

1537032-82-8

EY-Y0165104

Cas No.1537032-82-8

别名 N/A

化学名 N/A

分子式 N/A

Avelumab (Anti-Human PD-L1, Human Antibody).png

分子量 N/A

溶解度 Soluble in DMSO

储存条件 Store at -20°C
General tips  For obtaining a higher solubility , please warm the tube at 37 and shake it in the ultrasonic bath for a while.
Shipping Condition     Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述:
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab increases NK-cell lysis 3.1-fold (P=0.01) in JHC7 cells relative to isotype control. When the cells are treated with IFN-γ, Avelumab markedly enhances NK-cell lysis relative to isotype control in the following cell lines: JHC7 (7.56-fold; P=0.001), UM-Chor1 (7.34-fold; P<0.001), U-CH2 (2.6 fold; P=0.008), MUG-Chor1 (8.38-fold; P=0.0016). Avelumab effectively increases antibody-dependent cell-mediated cytotoxicity (ADCC) of both the non-cancer stem cell (CSC) and CSC subpopulations to the same degree[1]. Results also demonstrate that the addition of Avelumab increases the frequency of antigen-specific multifunctional CD8+ T cells by more than fivefold, relative to the isotype control in CEFT-stimulated peripheral blood mononuclear cells (PBMCs)[2].

Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant (P<0.01) reduction in the average tumor volume of the Avelumab-treated mice. Reduction in MB49 tumor growth in the mice treated with Avelumab is durable and leads to a significant (P<0.05) improvement in percent survival. Avelumab treatment of 10 mice with bladder tumors results in complete tumor regression in 8 mice, confirmed by histopathology. However, in mice depleted of either CD4 or CD8 cells, Avelumab treatment is much less effective in controlling bladder tumor burden with tumor breakthrough occurring in a higher frequency in mice depleted of CD4 T cells[3].

[1]. Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016 Jun 7;7(23):33498-511. [2]. Grenga I, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016 May 20;5(5):e83. [3]. Vandeveer AJ, et al. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res. 2016 May;4(5):452-62.


1537032-82-8;N/A;Avelumab (Anti-Human;

公司简介

上海一研生物科技有限公司Shanghai yiyan bio-technology Co. Ltd.主要从事免疫学、分子生物学和常规生化试剂等为一体的科研产品销售企业,公司自成立以来,秉承""全心全意服务于科研工作者""的企业理念,立足生物科技领域,运用生物技术和科研试剂,发展现代生物科技,为各类大中小医院及其它医疗机构、高等院校、科研院所、企事业单位提供优质的产品,服务生物科技领域的科学研究人员。 公司具有对普通货物、冷藏及冷冻仓库的存储、包装及运输能力。 公司将始终坚持信誉立业、以人为本、质量保证、诚信服务的宗旨,不断拼搏,开拓进取,与各界朋友携手共创美好未来。

成立日期 (11年)
注册资本 100
员工人数 50-100人
年营业额 ¥ 100万以内
经营模式 工厂,试剂
主营行业 生化试剂,抗体,细胞培养,分子生物学,免疫安全

Avelumab (Anti-Human PD-L1, Human Antibody)相关厂家报价 更多

内容声明
拨打电话 立即询价